Contact us


Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)

For more information, please visit

Patient Population Investigational Product(s) Phase Status
Metastatic Pancreatic Adenocarcinoma JAK Inhibitor III Open and Accruing